263 Modification of gastrointestinal health and ecology could be a treatment target, with a number of clinical examples that support the importance of identifying and managing gastrointestinal dysfunction in migraine sufferers
06 Confused about route If you are unsure whether to use injectable or oral material, stop and review the supplier label
Dose titration is key to minimising side effects
However, important limitations exist in the current evidence: Most studies have been relatively small with short follow-up periods Many participants had concurrent obesity, making it difficult to separate weight loss effects from direct effects on binge eating behaviour Long-term efficacy and safety data specifically for binge eating disorder are lacking The psychological and behavioural components of BED may require interventions beyond pharmacological appetite suppression There is no official link established by regulatory bodies between GLP-1 agonists and binge eating disorder treatment
is the only company in the United States with FDA-approved products containing semaglutide, identified under the trade names Rybelsus , Ozempic , and Wegovy
Frequently Asked Questions Why do GLP-1 medications cause constipation